Methods
This report is a retrospective chart review of one patient with MGRS and immunotactoid glomerulopathy. The patient reviewed this manuscript and provided written informed consent for the review of her medical records and publication of the results, per the Declaration of Helsinki.
Bortezomib, dexamethasone, and rituximab (BDR)3:
Cycle 1: bortezomib 1.3 mg/m2 IV on days 1, 4, 8, and 11; 21-day cycle.
Cycles 2-5: bortezomib 1.6 mg/m2 IV on days 1, 8, 15, and 22; 35-day cycle.
Cycles 2 and 5 only: dexamethasone 40 mg PO on days 1, 8, 15, and 22; rituximab 375 mg/m2 IV on days 1,8, 15, and 22; 35-day cycle.
Contact corresponding author for data acquisition and microscopy details.